J. Kollermann et B. Helpap, Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression, EUR UROL, 40(3), 2001, pp. 313-317
Objectives: Neuroendocrine (NE) differentiation in prostate cancer is belie
ved by some authors to play an important role in the development of androge
n resistance. However, there is little knowledge about the impact of short-
term neoadjuvant hormonal therapy on NE differentiation and on whether the
degree of tumor regression is linked with the extent of NE differentiation.
Methods: NE cells were detected by immunohistochemistry using a chromograni
n A antibody. The densities of NE cells in 20 pretreated and 20 nonpretreat
ed radical prostatectomy specimens were compared. Furthermore, we compared
the NE cell density in tumors with variable degrees of regression.
Results:The median percentage of tumor cells showing NE differentiation did
not significantly differ between pretreated and nonpretreated specimens (0
.61%, range 0.0-2.4%, vs. 1.47%, range 0.0-6.8%; p = 0.9896). Twelve nonreg
ressive/slightly regressive tumor foci and 12 strongly regressive tumor foc
i were assessed. The NE cell density did not differ significantly (p = 0.12
27).
Conclusions: Short-term neoadjuvant hormonal therapy does not induce releva
nt clonal propagation of NE cells. The degree of tumor regression following
short-term neoadjuvant hormonal therapy does not correlate with the extent
of NE differentiation. Copyright (C) 2001 S. Karger AG, Basel.